Previous 10 | Next 10 |
– Top-line Results Expected in the Fourth Quarter of 2023 – – Phase 1/2 Data Demonstrated Vimseltinib’s Best-in-Class Potential for the Treatment of TGCT – Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on d...
Deciphera Pharmaceuticals, Inc. (DCPH) Q4 2022 Earnings Conference Call February 07, 2023 8:00 AM ET Company Participants Jen Larson – Senior Vice President-Finance and Investor Relations Steve Hoerter – President and Chief Executive Officer Dan Martin ...
Deciphera Pharmaceuticals press release ( NASDAQ: DCPH ): Q4 GAAP EPS of -$0.60 misses by $0.04 . Revenue of $36.35M (+50.2% Y/Y) beats by $0.47M . Generated Gross Proceeds of Approximately $143.7 Million from Public Offering in January 2023 For further details s...
– Fourth Quarter 2022 Total Revenue of $36.3 Million and Full Year 2022 Revenue of $134.0 Million ; QINLOCK ® Net Product Revenue Increased 44% to $125.5 Million in 2022 Compared to 2021 – – Expects to Complete Enrollment in the MOTION Pivotal...
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in fireside chats at the fol...
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it will report its fourth quarter and full year 2022 financial results on Tu...
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the closing of its underwritten public offering of 7,986,111 shares of its common...
– Second-Line GIST Patients with Mutations in KIT Exon 11 + 17/18 Only Demonstrated Substantial Clinical Benefit from QINLOCK ® but Not Sunitinib – – Company Plans to Initiate the INSIGHT Pivotal Phase 3 Clinical Study in the Second Half of 2023 – ...
Deciphera Pharmaceuticals ( NASDAQ: DCPH ) has priced an underwritten public offering of 6,944,445 shares of its common stock at a public offering price of $18.00/share, for expected gross proceeds expected to be ~$125M. Underwriters are granted a 30-day option to purchase up to a...
Deciphera Pharma ( NASDAQ: DCPH ) said it it expects to offer and sell $125M shares of its common stock in an underwritten public offering. Deciphera would grant the underwriters a 30-day option to purchase up to an additional $18.75M of shares of common stock offered in the publi...
News, Short Squeeze, Breakout and More Instantly...
Deciphera Pharmaceuticals Inc. Company Name:
DCPH Stock Symbol:
NASDAQ Market:
Deciphera Pharmaceuticals Inc. Website:
– MOTION Phase 3 Data Demonstrate Robust Efficacy, Clinically Meaningful Improvements in Quality-of-Life Measures, and Well-Tolerated Safety Profile, Positioning Vimseltinib as Potential New TGCT Treatment – – Company Expects to Submit a New Drug Application (NDA) in ...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...